Encompass Health Corp (AMEX:EHC) insider Cheryl B. Levy sold 28,955 shares of the stock in a transaction dated Friday, August 3rd. The shares were sold at an average price of $78.00, for a total transaction of $2,258,490.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Shares of EHC stock traded down $0.42 on Friday, hitting $57.67. The company’s stock had a trading volume of 620,391 shares, compared to its average volume of 618,344. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.34 and a current ratio of 1.34. Encompass Health Corp has a fifty-two week low of $40.86 and a fifty-two week high of $59.29.
Encompass Health (AMEX:EHC) last released its quarterly earnings results on Wednesday, July 25th. The company reported $0.99 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.83 by $0.16. Encompass Health had a net margin of 8.67% and a return on equity of 23.56%. The business had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.03 billion. Encompass Health’s revenue for the quarter was up 10.5% compared to the same quarter last year. analysts anticipate that Encompass Health Corp will post 2.72 earnings per share for the current year.
Several equities analysts have recently weighed in on EHC shares. Piper Jaffray Companies raised shares of Encompass Health from a “neutral” rating to an “overweight” rating in a research report on Thursday, July 26th. Zacks Investment Research raised shares of Encompass Health from a “hold” rating to a “buy” rating and set a $84.00 price objective on the stock in a research report on Friday, July 27th. Mizuho reissued a “buy” rating and issued a $82.00 price objective on shares of Encompass Health in a research report on Thursday, July 26th. Credit Suisse Group increased their price objective on shares of Encompass Health from $66.00 to $80.00 and gave the company an “outperform” rating in a research report on Thursday, July 26th. Finally, SunTrust Banks reissued a “buy” rating and issued a $82.00 price objective on shares of Encompass Health in a research report on Friday, July 20th. Three analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $71.10.
Several hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new stake in Encompass Health during the first quarter worth about $622,184,000. JPMorgan Chase & Co. acquired a new stake in Encompass Health during the first quarter worth about $221,881,000. Lord Abbett & CO. LLC acquired a new stake in Encompass Health during the first quarter worth about $116,238,000. Victory Capital Management Inc. acquired a new stake in Encompass Health during the first quarter worth about $101,978,000. Finally, Northern Trust Corp acquired a new stake in Encompass Health during the first quarter worth about $88,764,000. Institutional investors and hedge funds own 93.18% of the company’s stock.
Encompass Health Company Profile
Encompass Health Corporation, formerly HealthSouth Corporation, is a provider of post-acute healthcare services, offering both facility-based and home-based post-acute services in 35 states and Puerto Rico through its network of inpatient rehabilitation hospitals, home health agencies and hospice agencies.
Receive News & Ratings for Encompass Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encompass Health and related companies with MarketBeat.com's FREE daily email newsletter.